Understanding how prostate cancer resists hormone therapy in low oxygen conditions
Adaptive resistance to AR inhibitors in hypoxia by GPT1
This study is looking at how prostate cancer cells learn to resist hormone treatments when there's not enough oxygen, focusing on a special enzyme called GPT1, with the hope of finding better ways to help patients get more effective treatments for advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11064001 on NIH RePORTER |
What this research studies
This research investigates how prostate cancer cells develop resistance to hormone therapies, particularly in low oxygen environments. The focus is on a specific enzyme called GPT1, which may play a crucial role in how cancer cells adapt their metabolism to survive despite treatment. By studying the mechanisms behind this resistance, the research aims to identify new strategies to improve the effectiveness of existing therapies. Patients may benefit from insights that could lead to more effective treatments for advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are undergoing or have undergone hormone therapy.
Not a fit: Patients with early-stage prostate cancer or those not receiving hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with hormone-resistant prostate cancer.
How similar studies have performed: Previous research has shown that understanding metabolic pathways in cancer can lead to breakthroughs in treatment, suggesting this approach has potential for success.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Qian, Zheng David — Oregon Health & Science University
- Study coordinator: Qian, Zheng David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.